Madrigal Pharmaceuticals (MDGL) Retained Earnings (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Retained Earnings data on file, last reported at -$2.2 billion in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$2.2 billion, down 16.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 16.5% YoY), and the FY2025 annual result was $873000.0, up 86.54% from the prior year.
• Retained Earnings retreated to -$2.2 billion in Q1 2026 per MDGL's latest filing, from $873000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $1.3 million in Q3 2024 and troughed at -$2.2 billion in Q1 2026.
• A 5-year average of -$815.1 million and a median of -$962.7 million in 2022 frame the typical range for Retained Earnings.
• On a YoY basis, Retained Earnings climbed as much as 100.1% in 2024 and fell as far as 1725284.88% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$962.7 million in 2022, then plunged by 38.81% to -$1.3 billion in 2023, then jumped by 100.04% to $468000.0 in 2024, then surged by 86.54% to $873000.0 in 2025, then plunged by 250374.91% to -$2.2 billion in 2026.
• Business Quant data shows MDGL's Retained Earnings at -$2.2 billion in Q1 2026, $873000.0 in Q4 2025, and -$2.0 billion in Q3 2025.